BACKGROUND: It is unknown whether extended treatment with pegylated interferon (PEG) and weight-based ribavirin (WBR) results in higher rates of sustained viro-logic response (SVR) among HCV-HIV coinfected patients compared with standard duration therapy. OBJECTIVE: The study aimed to measure rates of SVR among coinfected patients who received extended therapy with PEG plus WBR. METHODS: HCVHIV coinfected subjects were treated with PEG and WBR, and those who achieved early virologic response (EVR; ≥ 2 log decrease in HCV RNA from baseline or HCV RNA<600 IU/mL) at week 12 were eligible to continue treatment for 72 weeks. SVR (HCV RNA<60 IU/mL) was measured 24 weeks after treatment discontinuation. Predictors of SVR were assessed in simple and multivariate logistic regression. RESULTS: A total of 329 subjects enrolled at 36 sites. Of 184 subjects who achieved EVR, 169 entered Step 3: 89% male, 52% White, 29% Black, and 71% HCV treatment naïve. The overall SVR rate was 27% (95% CI, 22%-32%) among all subjects, and 33% (95% CI, 27%-40%) among the 223 who were HCV treatment naïve. In exploratory analyses, among 120 treatment-naïve subjects who entered Step 3, the SVR rate was 62% (95% CI, 52%-70%). In this subgroup, predictors of SVR were HCV genotype 2 or 3 (P = .03), HCV RNA <800,000 IU/mL at study entry (P = .05), and achievement of complete EVR (HCV RNA<600 IU/mL at week 12;P < .0001). CONCLUSION: Among all subjects, we observed a comparable overall SVR rate to prior studies of subjects treated for 48 weeks. Extended treatment with PEG and WBR may be beneficial to subsets of coinfected patients, specifically those who are treatment naïve and achieve complete EVR.
BACKGROUND: It is unknown whether extended treatment with pegylated interferon (PEG) and weight-based ribavirin (WBR) results in higher rates of sustained viro-logic response (SVR) among HCV-HIV coinfectedpatients compared with standard duration therapy. OBJECTIVE: The study aimed to measure rates of SVR among coinfected patients who received extended therapy with PEG plus WBR. METHODS:HCVHIV coinfected subjects were treated with PEG and WBR, and those who achieved early virologic response (EVR; ≥ 2 log decrease in HCV RNA from baseline or HCV RNA<600 IU/mL) at week 12 were eligible to continue treatment for 72 weeks. SVR (HCV RNA<60 IU/mL) was measured 24 weeks after treatment discontinuation. Predictors of SVR were assessed in simple and multivariate logistic regression. RESULTS: A total of 329 subjects enrolled at 36 sites. Of 184 subjects who achieved EVR, 169 entered Step 3: 89% male, 52% White, 29% Black, and 71% HCV treatment naïve. The overall SVR rate was 27% (95% CI, 22%-32%) among all subjects, and 33% (95% CI, 27%-40%) among the 223 who were HCV treatment naïve. In exploratory analyses, among 120 treatment-naïve subjects who entered Step 3, the SVR rate was 62% (95% CI, 52%-70%). In this subgroup, predictors of SVR were HCV genotype 2 or 3 (P = .03), HCV RNA <800,000 IU/mL at study entry (P = .05), and achievement of complete EVR (HCV RNA<600 IU/mL at week 12;P < .0001). CONCLUSION: Among all subjects, we observed a comparable overall SVR rate to prior studies of subjects treated for 48 weeks. Extended treatment with PEG and WBR may be beneficial to subsets of coinfected patients, specifically those who are treatment naïve and achieve complete EVR.
Authors: Donald M Jensen; Timothy R Morgan; Patrick Marcellin; Paul J Pockros; K Rajender Reddy; Stephanos J Hadziyannis; Peter Ferenci; Andrew M Ackrill; Bernard Willems Journal: Hepatology Date: 2006-05 Impact factor: 17.425
Authors: José M Sánchez-Tapias; Moisés Diago; Pedro Escartín; Jaime Enríquez; Manuel Romero-Gómez; Rafael Bárcena; Javier Crespo; Raúl Andrade; Eva Martínez-Bauer; Ramón Pérez; Milagros Testillano; Ramón Planas; Ricard Solá; Manuel García-Bengoechea; Javier Garcia-Samaniego; Miguel Muñoz-Sánchez; Ricardo Moreno-Otero Journal: Gastroenterology Date: 2006-08 Impact factor: 22.682
Authors: Luz Martin-Carbonero; Marina Nuñez; Ana Mariño; Federico Alcocer; Llucía Bonet; Javier García-Samaniego; Pilar López-Serrano; Miguel Cordero; Joseba Portu; Vincent Soriano Journal: AIDS Date: 2008-01-02 Impact factor: 4.177
Authors: Marina Núñez; Celia Miralles; Miguel Angel Berdún; Elena Losada; Koldo Aguirrebengoa; Antonio Ocampo; Piedad Arazo; Manuel Cervantes; Ignacio de Los Santos; Isabel San Joaquín; Santiago Echeverría; María José Galindo; Victor Asensi; Pablo Barreiro; Julio Sola; Juan José Hernandez-Burruezo; Josep Maria Guardiola; Miriam Romero; Javier García-Samaniego; Vincent Soriano Journal: AIDS Res Hum Retroviruses Date: 2007-08 Impact factor: 2.205
Authors: Marina Núñez; Ana Mariño; Angel Mariño; Celia Miralles; Miguel A Berdún; Julio Sola; Juan Jose Hernandez-Burruezo; Maria Jose Galindo; Pablo Barreiro; Luz Martin-Carbonero; Vincent Soriano Journal: J Acquir Immune Defic Syndr Date: 2007-08-01 Impact factor: 3.731
Authors: Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein Journal: Nature Date: 2009-08-16 Impact factor: 49.962
Authors: Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: Valerianna K Amorosa; Anne Luetkemeyer; Minhee Kang; Victoria A Johnson; Triin Umbleja; David W Haas; Suria Yesmin; Matthew C Bardin; Ray T Chung; Beverly Alston-Smith; Pablo Tebas; Marion G Peters Journal: HIV Clin Trials Date: 2013 Nov-Dec
Authors: Kara W Chew; Lei Hua; Debika Bhattacharya; Adeel A Butt; Lorelei Bornfleth; Raymond T Chung; Janet W Andersen; Judith S Currier Journal: Open Forum Infect Dis Date: 2014-12-03 Impact factor: 3.835
Authors: Roger Bedimo; Minhee Kang; Pablo Tebas; Edgar T Overton; Kimberly Hollabaugh; Grace McComsey; Debika Bhattacharya; Christopher Evans; Todd T Brown; Babafemi Taiwo Journal: AIDS Res Hum Retroviruses Date: 2015-11-24 Impact factor: 2.205